Tubulin polymerization-IN-2 

Tubulin polymerization-IN-2 is a potent anticancer agent targeting to β-tubulin with an IC₅₀ value of 0.92 μM. Tubulin polymerization-IN-2 shows promising activity against various leukemia, non-small lung, renal, prostate, and breast cancer cell lines^[1].

IC50: 0.92 μM (tubulin)^[1]

Tubulin polymerization-IN-2 (compound 2b) shows anti-cancer activity against epidermal carcinoma and breast carcinoma with IC₅₀s of 2.3 μM (KB) and 2.2 μM (BT-549), respectively^[1].
Tubulin polymerization-IN-2 (0.342 μM; 24 h) inhibits DNA synthesis or repair, arrests cell cycle at S phase in MCF-7 cells^[1].
Tubulin polymerization-IN-2 (0.342 μM; 24 h) induces cell apoptosis by decreasing Bax, APAF-1, and caspase-3 expression and increasing BCL-2 mRNA abundance^[1].
Tubulin polymerization-IN-2 (0.01, 0.1, 1, 10 μM; 1 h) has strong interactions on β-tubulin polymerization, with K_i value of 0.09 μM^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

314.29

C₁₇H₁₂F₂N₂O₂

2873399-22-3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Elshemy HAH, et al. Development of potential anticancer agents and apoptotic inducers based on 4-aryl-4H chromene scaffold: Design, synthesis, biological evaluation and insight on their proliferation inhibition mechanism. Bioorg Chem. 2022 Jan;118:105475.  [Content Brief]